In the Comparing Alternative Ranibizumab Dosages for Safety and Efficacy (CARE)-ROP study, ranibizumab was successful at reducing severe ROP at 24% the adult dose and did not reduce serum VEGF levels; however, some infants experienced recurrent ROP and required additional treatments of ranibizumab [10]. This evidence concerns the gene VEGFA and retinopathy of prematurity.